VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
Second Generation GENOSYL® DS is the first and only Inhaled…
VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System
Financing led by Petrichor strengthens VERO Biotech's position…
VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
This novel GENOSYL® system represents another…
Georgia Bio Awards VERO Biotech the 2022 Golden Helix Innovation Award and Deal of the Year Award
Atlanta-based innovative company is recognized for its flagship…
VERO Biotech Receives Funding from MVM Partners to Accelerate Growth
Investment from MVM Partners to support the growth of…
VERO Biotech Secures $50 Million Funding from Runway Growth Capital
A senior secured term loan will support the further development…
FDA Approves Interhospital Patient Transport Use of VERO Biotech’s GENOSYL® Delivery System, Resulting in the Broadest Label in the Inhaled Nitric Oxide Space
The GENOSYL® DS facilitates patient treatment in interhospital…
Home Use of GENOSYL® Delivery System (DS) to Administer GENOSYL® (nitric oxide) gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine
Clinicians report on first at-home treatment of COVID-19 patient…
VERO Biotech Commits to Atlanta Healthcare Providers, Patients and Workforce During COVID-19 Pandemic
Atlanta-based biotech provides innovative portable inhaled nitric…